Contributors: Equipe 7 : EPICEA - Epidémiologie des cancers de l'enfant et de l'adolescent (CRESS - U1153); Université Paris Descartes - Paris 5 (UPD5)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)); Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM); Telethon KIDS Institute; The University of Western Australia (UWA); Département de cancérologie de l'enfant et de l'adolescent Gustave Roussy; Institut Gustave Roussy (IGR); Sercice Hématologie, immunologie et oncologie pédiatrique CHU Toulouse; Pôle Enfants CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Centre Léon Bérard Lyon; Oscar Lambret Comprehensive Cancer Center; Service d'Immuno-Hémato-Oncologie Pédiatrique; Centre Hospitalier Universitaire d'Angers (CHU Angers); PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM); Université Grenoble Alpes - UFR Médecine (UGA UFRM); Université Grenoble Alpes 2016-2019 (UGA 2016-2019 ); Institut Curie Paris; Service de neurochirurgie pédiatrique CHU Necker; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Necker - Enfants Malades AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); CHU de Bordeaux Pellegrin Bordeaux; Registre National des Tumeurs Solides de l'Enfant (RNTSE); Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Cancéropôle du Grand Est; Registre National des Hémopathies malignes de l'Enfant (RNHE); Institut de Veille Sanitaire (INVS)-Institut National de la Santé et de la Recherche Médicale (INSERM); INSERM, the Ligue National Contre le Cancer (LNCC), the Fondation de France, the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), the Agence Française de Sécurité Sanitaire de l’Environnement et du Travail (AFSSET), the Association pour la Recherche sur le Cancer (ARC), the Agence Française de Sécurité Sanitaire des Produits de Santé (ANSM), the Agence Française de Sécurité Sanitaire de l’Environnement et du Travail (ANSES), the association Cent pour sang la vie, the Institut National du Cancer (INCa) and the Agence Nationale de la Recherche (ANR), and Cancéropôle Ile de France.; ANR-10-COHO-0009,HOPE-EPI,HOPE-Epidémiologie – Recherche épidémiologique en Hémato-Oncologie Pediatrique(2010)
نبذة مختصرة : International audience ; Purpose: Although some specific genetic syndromes such as neurofibromatosis (NF) have been identified as risk factor of childhood brain tumors (CBT), the potential role of inherited susceptibility in CBT has yet to be elucidated.Methods: To further investigate this, we conducted a pooled analysis of two nationwide case-control studies ESCALE and ESTELLE. The mothers of 509 CBT cases and 3,102 controls aged under 15 years who resided in France at diagnosis/interview, frequency-matched by age and gender, responded to a telephone interview conducted by trained interviewers. Pooled odds ratio (OR) and 95% confidence intervals (95% CI) were estimated using unconditional logistic regression.Results: CBT was significantly associated with the family history of cancer in relatives (OR 1.2, 95% CI 1.0-1.5). The OR was slightly higher for maternal relatives than for paternal relatives, and when at least two relatives had a history of cancer. CBT was significantly associated with a family history of brain tumor (OR 2.1, 95% CI 1.3-3.7). This association seemed stronger for first-degree relatives (mother, father, and siblings), for whom, by contrast, no association was seen for cancers other than CBT. No specificity by CBT subtypes or by age of the children were found for any of these findings.Conclusion: Our findings support the hypothesis of a familial susceptibility of CBT, not due to being a known NF carrier.
Processing Request
No Comments.